

Harvard Medical School Curriculum Vitae

Date Prepared: May 8, 2023
Name: Benjamin N. Rome
Office Address: Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital
1620 Tremont Street, Suite 3030
Boston, MA 02120
Home Address: 10 Brooks Road
Wayland, MA 01778
Work Phone: 617-278-0930
Work Email: brome@bwh.harvard.edu
Work Fax: 617-232-8602
Place of Birth: Burlington, VT

Education

2010	BA (with honors, <i>summa cum laude</i>)	Community Health	Brown University, Providence, RI
2016	MD	Medicine	Harvard Medical School, Boston (HMS), MA
2021	MPH	Clinical Effectiveness	Harvard T.H. Chan School of Public Health (HSPH), Boston, MA

Postdoctoral Training

6/2016-6/2019	Resident	Internal Medicine	Brigham and Women's Hospital (BWH), Boston, MA
7/2019-12/2020	Postdoctoral Research Fellow	Pharmacoepidemiology and Pharmacoeconomics (Mentor: Aaron Kesselheim)	BWH

Faculty Academic Appointments

1/2021-present	Instructor	Medicine	HMS
----------------	------------	----------	-----

Appointments at Hospitals/Affiliated Institutions

7/2010-6/2012	Clinical Research Assistant	Orthopedic and Arthritis Center for Outcomes Research	BWH
7/2019-present	Associate Physician	Pharmacoepidemiology and Pharmacoeconomics	BWH

Other Professional Positions

2019-present	Consultant	Alosa Health	3 hr/week
--------------	------------	--------------	-----------

Major Administrative Leadership Positions

Local

2021-present	Site Co-Director, T32 Funded Harvard Medical School Fellowship in General Medicine and Primary Care	Division of Pharmacoepidemiology and Pharmacoeconomics, BWH
2022-present	Assistant Director, Management and Leadership Pathway, Internal Medicine Residency	Department of Medicine, BWH
2022-present	Assistant Director of Health Services Research, Program On Regulation, Therapeutics, and Law (PORTAL)	Division of Pharmacoepidemiology and Pharmacoeconomics, BWH
2022-present	Assistant Course Director, Effectiveness Research with Longitudinal Healthcare Databases (EPI 253)	HSPH

Committee Service

Local

2021-present	Admissions Committee, Subcommittee 4 member	HMS
--------------	---	-----

Professional Societies

2012-2021	American Medical Association	Member
2012-present	Massachusetts Medical Society	Member
2013-2021	American College of Physicians	Member
2020-present	Society of General Internal Medicine	Member
2021-present	AcademyHealth	Member

Editorial Activities

Ad hoc Reviewer

Annals of Internal Medicine
Circulation: Cardiovascular Quality and Outcomes
Clinical Infectious Diseases
Clinical Pharmacology & Therapeutics
JAMA
JAMA Internal Medicine
JAMA Health Forum
JAMA Network Open
Journal of General Internal Medicine
Journal of Law, Medicine & Ethics

Health Affairs
Health Services Research
Open Forum Infectious Diseases
PLoS One
Value in Health

Honors and Prizes

2010	Best Undergraduate Research Poster Presentation	Program in Public Health	Brown University
2011	Partners in Excellence Team Award	Orthopaedic and Arthritis Center BWH for Outcomes Research	
2016	Gerald Foster Prize	Admissions Committee	HMS
2021	Finalist, Milton W. Hamolsky Junior Faculty Scientific Presentation Award	2021 Annual Meeting	Society of General Internal Medicine
2022	Elected Scholar	Emerging Leaders in Health and Medicine	National Academy of Medicine, Washington, DC

Report of Funded and Unfunded Projects

Funding Information

Past

2019-2020	Identifying Opportunities for Improvement During the Transition from Brand-name Exclusivity to Generic Competition Anthem Public Policy Institute Co-Investigator (PI: Aaron S. Kesselheim) We investigated factors that influence how quickly cheaper generic drugs replace brand-name drugs once market exclusivity expires, the effect of manufacturer coupons, and whether policies limiting coupon use might reduce spending on brand-name prescription drugs.
2021-2022	Impact of Authorized Generics on Market Dynamics and Prices Anthem Public Policy Institute Principal Investigator This project investigated the trends in use of authorized generics, compared spending on authorized generics compared with traditional generics, and identified cases when authorized generics might be used to reduce generic competition.

Current

2020-2024	Pharmaceutical Pricing and Policy Expertise Massachusetts Health Policy Commission Co-Investigator (PI: Aaron S. Kesselheim) I am co-leading an interdisciplinary team advising the Health Policy Commission on the implementation and execution of their new statutory authority to review prices for expensive drugs and promote value-based pharmaceutical pricing within the Massachusetts Medicaid Program.
-----------	--

2021-2024	Prescription Drug Affordability Board Colorado Division of Insurance Co-Principal Investigator (Co-PIs: Aaron S. Kesselheim and Jerry Avorn) (\$130,000) I am co-leading an interdisciplinary team assisting the state of Colorado's newly established Prescription Drug Affordability Board, which is tasked with identifying high-cost drugs, assessing affordability, and setting upper payment limits for drugs deemed to be unaffordable.
2022-2023	Proposal to Support State Prescription Drug Affordability Boards National Academy for State Health Policy Co-Principal Investigator (Co-PIs: Aaron S. Kesselheim and Jerry Avorn) (\$300,000) Selected in a competitive bidding process to advise 6 state prescription drug affordability boards by implementing novel strategies to lower prescription drug prices and improve affordability for patients.
2022-2024	Use and Spending on Low-value Specialty Medications Elevance Health Public Policy Institute Principal Investigator (\$298,109) This project aims to identify specialty medications to treat plaque psoriasis, multiple sclerosis and Crohn's disease that are priced out of proportion to the clinical benefit they offer patients, and to estimate savings that could be achieved from better alignment of prices with value.
2023-2026	Shaping a New Era for US Prescription Drug Policy: Optimizing Evidence, Accessibility, Regulation, and Innovation Arnold Ventures Co-investigator (PI: Aaron S. Kesselheim) This project supports the Program On Regulation, Therapeutics, And Law (PORTAL) in pursuing research related to two policies that affect the regulation, evidence-based innovation, and affordability of prescription drugs.

Projects Submitted for Funding

Submitted 6/2023	Medicare Part D Prescription Drug Coverage Changes in the Inflation Reduction Act: Impact on the Health of Older Adults with Diabetes National Institutes of Health/National Institute on Aging R01 Principal Investigator (\$2,415,960 requested) This grant proposes to evaluate whether Medicare Part D prescription drug coverage reforms enacted by the Inflation Reduction Act of 2022 are associated with changes in medication adherence and clinical outcomes among older adults with diabetes.
---------------------	---

Report of Local Teaching and Training

Teaching of Students in Courses

HMS/HSDM/DMS Courses

2020-present	Medications and Evidence (AISC 624) 3rd year medical students	HMS 1 hour-long lecture 2 hour-long small group sessions
--------------	---	---

2021-present	Essentials of the Profession II (PWY 220), 3 rd and 4 th year medical students	HMS 7 hours of small group sessions about Clinical Epidemiology and Population Health
2022	Translational Pharmacology – The Science of Therapeutic Discovery and Development (BCMP 301qc), master's students	HMS 1 hour-long small group session
2023-present	Essentials of the Profession I (PWY 120), 1 st year medical students	HMS 5 hours of small group sessions about health policy

Other Harvard University courses

2022-present	Effectiveness Research with Longitudinal Healthcare Databases (EPI 253) Master's students	HSPH 1 hour lecture, 5 hours of small groups
--------------	---	---

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

2020-22	Introduction to Virtual Clinic Visits 1 st Year Residents	BWH 4 hour-long lectures per year
2020-present	Introduction to Division of Pharmacoepidemiology and Pharmacoeconomics 2 nd Year Residents, Management and Leadership Pathway	BWH Moderate a 3-hour annual session
2022	Why are my patient's prescription medications so expensive?... and what can I do about it? 1 st year Residents, ambulatory & primary care curriculum	BWH 4 hour-long lecture

Clinical Supervisory and Training Responsibilities

2021-present	Preceptor, Phyllis Jen Center for Primary Care Internal medicine residents	BWH One half-session per week
--------------	--	----------------------------------

Laboratory and Other Research Supervisory and Training Responsibilities

2021-present	Research supervision Postdoctoral fellows (average of 1-2 fellows/year)	Division of Pharmacoepidemiology and Pharmacoeconomics, BWH One-hour fellowship meeting per month; 1:1 supervision 1 hour/week per fellow
--------------	--	---

Formally Mentored Harvard Medical, Dental, Graduate, and Undergraduate Students

2020-present	Simon Gunter, HMS and Harvard Business School Class of 2024 Published 2 manuscripts about the economic impact of the FDA's Unapproved Drugs Initiative and 1 about the use of authorized generic drugs.	
--------------	--	--

- 2021-present Kimberly Feng, HMS Class of 2023
Conducting a project studying patient out-of-pocket costs on expensive biologic medications after the introduction of biosimilar competition. One manuscript published, another in preparation.
- 2022-present Sarosh Nagar Harvard College Class of 2024
Research co-mentor, published 1 articles about prescription drug pricing policies in the Inflation Reduction Act, 2 additional manuscripts, including 1 first-authorship, in press.

Other Mentored Trainees and Faculty

- 2020-present Aayan Patel / Undergraduate Student, Stanford University, Stanford, CA
Career stage: Undergraduate student. *Mentoring role:* Research co-mentor.
Accomplishments: First-authored manuscript published while Aayan was a high school student participating in the Research Science Institute at MIT. Second manuscript in press.
- 2021-2022 Bryan Walsh, JD / Research Fellow, Pharmacoepidemiology and Pharmacoeconomics, BWH
Career stage: Postdoctoral fellow. *Mentoring role:* Research co-mentor.
Accomplishments: Two first-authored manuscript published.
- 2021-2022 Anjali Deshmukh, MD, JD / Research Fellow, Pharmacoepidemiology and Pharmacoeconomics, BWH
Career stage: Postdoctoral fellow. *Mentoring role:* Research co-mentor.
Accomplishments: Manuscripts in press.
- 2021-present Hussain Lalani, MD, MPH / Research Fellow, Pharmacoepidemiology and Pharmacoeconomics, BWH
Career stage: Postdoctoral fellow. *Mentoring role:* Research co-mentor.
Accomplishments: Three first-author manuscripts published, several in preparation. Workshop accepted for Society of General Internal Medicine Annual Meeting in 2023.
- 2022 Fanual Berhe / Undergraduate Intern, Pharmacoepidemiology and Pharmacoeconomics, BWH
Career stage: Vanderbilt University Undergraduate participating in summer internship for underrepresented minority students. *Mentoring role:* Project co-mentor
Accomplishments: Completed a capstone project evaluating the cost and evidence of FDA-approved treatments for spinal muscular atrophy, which Fanual presented to the Division of Pharmacoepidemiology and Pharmacoeconomics
- 2022-present Catherine Hwang, MD, MPH / Research Fellow, Pharmacoepidemiology and Pharmacoeconomics, BWH
Career stage: Postdoctoral fellow. *Mentoring role:* Research co-mentor.
Accomplishments: Multiple first-author manuscripts in progress.
- 2022-present Sonya Davey, MD / Resident, Department of Medicine, BWH
Career stage: Internal medicine resident. *Mentoring role:* Research mentor.
Accomplishments: First-author manuscript in progress.
- 2022-present Dongze Hong, PhD / Research Fellow, Pharmacoepidemiology and Pharmacoeconomics, BWH

Career Stage: Postdoctoral fellow. *Mentoring role:* Research co-mentor.
Accomplishments: Manuscript in progress.

2022-present Edward Cliff, MBBS, MPH / Research Fellow, Pharmacoepidemiology and Pharmacoeconomics, BWH

Career Stage: Postdoctoral fellow. *Mentoring role:* Research co-mentor.
Accomplishments: One manuscript in press, another under review.

2022-present Adam Raymakers, PhD / Research Fellow, Pharmacoepidemiology and Pharmacoeconomics, BWH

Career Stage: Postdoctoral fellow. *Mentoring role:* Research co-mentor.
Accomplishments: Multiple manuscripts in progress.

Formal Teaching of Peers (e.g., CME and other continuing education courses)

No presentations below were sponsored by outside entities.

2023	Prescription Drug Pricing Policy in the US: Challenges and Future Directions Evidence, Insight & Strategy for Optimizing Health Benefits, HMS Executive Education program for the International Foundation of Employee Benefit Plans	1.25 Hour Lecture Boston, MA
------	---	---------------------------------

Local Invited Presentations

2019	Comparative effectiveness and safety of first-line antihypertensive drug classes / Journal Club Division of Pharmacoepidemiology and Pharmacoeconomics, BWH
2020	Remdesivir for the Treatment of Covid-19 / Journal Club Division of Pharmacoepidemiology and Pharmacoeconomics, BWH
2020	Oral Anticoagulant Out-of-Pocket Costs and Adherence / Invited Talk Division of Pharmacoepidemiology and Pharmacoeconomics, BWH
2022	Data Resources, Drug Prices and Payment / PORTAL Retreat Division of Pharmacoepidemiology and Pharmacoeconomics, BWH

Report of Regional, National and International Invited Teaching and Presentations

Invited Presentations and Courses

No presentations below were sponsored by outside entities.

Regional

2019	Therapeutic Interchange: Opportunities and Challenges to Reduce Unnecessary Prescription Drug Spending / Invited lecture Blue Cross Blue Shield of Massachusetts, Boston, MA
2021	Pharmaceutical Access, Cost & Transparency / Testimony Massachusetts Joint Committee on Health Care Financing, Boston, MA (Virtual)

National

2020	Drug Approval During the Covid-19 Pandemic: Following the Evidence / Testimony US House Committee on Science, Space, and Technology; Subcommittee on Investigations & Oversight/Hearing on Repurposing Therapeutic Drugs for Covid-19: Research Challenges and Opportunities, Washington, DC (Virtual)
2022	A New Era in Prescription Drug Pricing Policy: The Inflation Reduction Act of 2022 / Invited Seminar University of Pittsburgh Health Services Research Seminar Series, Pittsburgh, PA (Virtual)
2023	Medicare Drug Price Negotiation Program: Initial Memorandum / Invited Comments Centers for Medicare and Medicaid Services, Baltimore, MD (Remote)

National Abstract Oral Presentations

2021	Simultaneous Administration of the Flu and Zoster Vaccines and Subsequent Receipt of the Flu Vaccine [Hamolsky Junior Faculty Award Finalist] Society of General Internal Medicine Annual Meeting (Virtual)
------	---

Report of Clinical Activities and Innovations

Current Licensure and Certification

2016	Massachusetts Medical License
2019	American Board of Internal Medicine

Practice Activities

2019-present	Primary Care	Phyllis Jen Center for Primary Care, BWH	One half-day session per week
2019-2021	Urgent Care	Phyllis Jen Center for Primary Care, BWH	One half-day session per week

Clinical Innovations

Virtual Visits in Primary Care (2020)	During the Covid-19 pandemic, the Phyllis Jen Center for Primary Care at BWH briefly closed to in-person visits and transitioned entirely to telemedicine appointments. I led the efforts within our practice to develop virtual visit workflows and trained residents and attending physicians about how to effectively use the hospital's virtual visit technology.
--	---

Report of Education of Patients and Service to the Community

Activities

No presentations below were sponsored by outside entities.

2021	Myths and Facts of Drug Pricing Proposals / Panel member Doctors for America, Washington, DC (Virtual)
2022	Economics of Prescription Drugs in the US / Lecture Generation Patient (Virtual)

2023 Negotiating Prescription Drugs for Medicare – Will it really work? / Lecture
Single Payer Action Network (SPAN) Ohio, Pepper Pike, OH (Virtual)

Educational Material for Patients and the Lay Community

No educational materials below were sponsored by outside entities.

Books, Monographs, Articles and Presentations in Media

1. **Rome BN.** Is Bariatric Surgery Cost Effective? Ed. Jones DB. The Medical Student Notebook. Bariatric Times, 2015;12(3):8-10. Available: <http://bariatrictimes.com/is-bariatric-surgery-cost-effective>.
2. Brown B, **Rome B.** To Cut Prescription Drug Spending, Stop Delays for Generic Competition. *Bill of Health* [Blog]. Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. 2010 Jul 24. Available: <https://blog.petrieflom.law.harvard.edu/2020/07/24/prescription-drug-costs-generic-competition/>.
3. Lalani HS, **Rome BN**, Kesselheim AS. Medicare could save \$3 billion by buying drugs like Mark Cuban [Opinion]. *Washington Post*. July 7, 2022. Available: <https://www.washingtonpost.com/opinions/2022/07/07/medicare-save-three-billion-drugs-mark-cuban/>.
4. **Rome BN**, Egilman AC, Kesselheim AS. Prices for New Drugs Are Rising 20 Percent a Year. Congress Needs to Act [Opinion, Guest Essay]. *New York Times*. June 8, 2022. Available: <https://www.nytimes.com/2022/06/08/opinion/us-drug-prices-congress.html>.
5. Bendickson L, **Rome BN.** Makena Is Just the Latest in Accelerated Approval Mayhem — Congress must take action to reform the process [Opinion]. *Medpage today*. October 24, 2022. Available: <https://www.medpagetoday.com/opinion/second-opinions/101383>.
6. Egilman, AC, Kesselheim AS, **Rome BN.** Is It Business as Usual for the Drug Industry? Drugmakers continue to raise prices despite new legislation [Opinion]. *Medpage today*. March 28, 2023. Available: <https://www.medpagetoday.com/opinion/second-opinions/103761>.

Recognition

2020	Coverage: Medication approval during COVID-19 pandemic	Politico: https://www.politico.com/news/2020/04/17/drug-makes-coronavirus-cure-trump-193174 (April 17, 2020) USA Today: https://www.usatoday.com/story/news/health/2020/04/18/hydroxychloroquine-coronavirus-creates-shortage-lupus-drug/5129896002/ (April 18, 2020)
2021	Flu/Shingles Shot Combo May Hurt Future Flu Vaccine Uptake	Medscape: https://www.medscape.com/viewarticle/963434 (November 22, 2021)
2022	Prices of new drugs have soared. Will legislation be able to stop it?	NBC News: https://www.nbcnews.com/health/health-news/prices-new-drugs-soared-will-legislation-able-stop-rcna32138 (June 7, 2022)

		Everyday Health: https://www.everydayhealth.com/public-health/the-cost-of-new-drugs-may-keep-many-patients-from-accessing-essential-medications/ (June 15, 2022) Yahoo: https://finance.yahoo.com/news/price-prescription-drugs-skyrocketing-223952626.html (June 7, 2022) Boston Herald: https://www.bostonherald.com/2022/06/07/prices-for-new-brand-name-prescription-drugs-spike-brigham-and-womens-hospital-research/ (June 7, 2022)
2022	Mark Cuban's pharmacy could have saved Medicare \$3.6 billion, researchers find	The Dallas Morning News: https://finance.yahoo.com/news/price-prescription-drugs-skyrocketing-223952626.html (June 21, 2022)
2022	Don't Cancel Your Colonoscopy Just Yet	Washington Post: https://www.washingtonpost.com/politics/2022/07/22/bidens-claim-that-drug-price-bill-will-help-fight-inflation/ (July 22, 2022)
2022	Biden's claim that drug-price bill will help fight inflation'	Washington Post: https://www.washingtonpost.com/politics/2022/07/22/bidens-claim-that-drug-price-bill-will-help-fight-inflation/ (July 22, 2022)
2022	Senate drug price bill is limited to Medicare. Here's what it means for those with private insurance	CNN: https://www.cnn.com/2022/08/09/politics/senate-medicare-drug-cost-bill-private-insurance/index.html (August 9, 2022)
2022	Hemophilia patients react to new \$3.5 million gene therapy	Business Insider: https://www.businessinsider.com/hemophilia-a-patients-react-to-new-3-million-gene-therapy-2022-11 (December 5, 2022)
2023	Why drugmakers have raised prices on nearly 1,000 drugs so far this year	USA Today: https://www.usatoday.com/story/news/health/2023/01/30/drug-price-increases-2023/11084913002/ (January 30, 2023)
2023	Medicare negotiating drug prices will likely save the U.S. billions, study says	NBC News: https://www.nbcnews.com/health/health-news/medicare-negotiating-drug-prices-will-likely-us-billions-study-says-rcna67820 (January 27, 2023) Endpoints News: https://endpts.com/iras-price-negotiation-provision-wouldve-saved-medicare-26-5b-from-2018-to-2020-jama-study-says/ (January 30, 2023)

2023	Coverage: First biosimilar competition for adalimumab (Humira)	Health Day: https://consumer.healthday.com/medicare-will-save-u-s-billions-negotiating-drug-prices-2659327279.html (January 31, 2023) Reuters: https://www.reuters.com/business/healthcare-pharmaceuticals/abbvies-humira-gets-us-rival-costs-could-stay-high-2023-01-31/ (February 1, 2023) Daily Mail: https://www.dailymail.co.uk/news/article-11697851/Big-pharma-company-AbbVie-114bn-Humira-tying-competitors-litigation.html (January 31, 2023)
2023	Coverage: Insulin price cuts	Politico: https://www.politico.com/newsletters/prescription-pulse/2023/03/07/eli-lilly-insulin-cost-cuts-00085724 (March 7, 2023) Washington Post: https://www.washingtonpost.com/business/2023/03/16/insulin-price-cuts-could-lift-profits-for-eli-lilly-and-novo-nordisk/1331efe2-c3fe-11ed-82a7-6a87555c1878_story.html (March 16, 2023)

Report of Scholarship

* Indicates co-first authorship

** Indicates mentee as co-author

Peer-reviewed publications in print or other media

Research investigations

1. Losina E, Thornhill TS, **Rome BN**, Wright J, Katz JN. The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic. *J Bone Joint Surg. Am* 2012; 94(3):201-7. Doi: 10.2106/JBJS.J.01958.
2. Losina E, Weinstein AM, Reichmann WM, Burbine SA, Solomon DH, Daigle ME, **Rome BN**, Chen SP, Hunter DJ, Suter LG, Jordan JM, Katz JN. Lifetime risk and age of diagnosis of symptomatic knee osteoarthritis in the US. *Arthritis Care Res (Hoboken)*. 2013; 65(5):703-11. Doi:10.1002/acr.21898.
3. Weinstein AM*, **Rome BN***, Reichmann WM, Collins JE, Burbine SA, Thornhill TS, Wright J, Katz JN, Losina E. Estimating the burden of total knee replacement in the United States. *J Bone Joint Surg Am*. 2013; 95(5):385-92. Doi:10.2106/JBJS.L.00206.
4. Katz JN, Brophy RH, Chaisson CE, de Chaves L, Cole BJ, Dahm DL, Donnell-Fink LA, Guermazi A, Haas AK, Jones MH, Levy BA, Mandl LA, Martin SD, Marx RG, Miniaci A, Matava MJ, Palmisano J, Reinke EK, Richardson BE, **Rome BN**, Safran-Norton CE, Skonieczki DJ, Solomon DH, Smith MV, Spindler KP, Stuart MJ, Wright J, Wright RW, Losina E. Surgery versus physical therapy for a meniscal tear and osteoarthritis. *N Eng J Med*. 2013; 368(18):1675-84. Doi:10.1056/NEJMoa1301408.

5. Collins JE, **Rome BN**, Daigle ME, Lerner V, Katz JN, Losina E. A Comparison of Patient-Reported and Measured Range of Motion in a Cohort of Total Knee Arthroplasty Patients. *J Arthroplasty*. 2014; 29(7):1378-1382. Doi:10.1016/j.arth.2014.02.023.
6. **Rome BN**, Kramer DB, Kesselheim AS. FDA Approval of Cardiac Implantable Electronic Devices via Original and Supplement Premarket Approval Pathways, 1979-2012. *JAMA*. 2014; 311(4):385-91. Doi:10.1001/jama.2013.284986.
 - Goodman SN, Redberg RF. Opening the FDA Black Box. [Editorial] *JAMA*. 2014;311(4):361-63. Doi:10.1001/jama.2013.283946.
 - McCarthy M. Quality of evidence behind FDA approvals varies widely. [Review] *BMJ*. 2014; 348:g1075. Doi:10.1136/bmj.g1075.
7. Kesselheim AS, **Rome BN**, Sarpatwari A, Avorn J. Six-Month Market Exclusivity Extensions to Promote Research Offer Substantial Returns for Many Drug Makers. *Health Aff (Millwood)*. 2017 Feb 1;36(2):362-70. Doi:10.1377/hlthaff.2016.1340.
 - Bronstein M, Kakkis E, Fajgenbaum D, Chambers C. For rare disease patients, a pathway to hundreds of new therapies. [Editorial] *Health Affairs Blog*. March 21, 2017. Available at: <https://www.healthaffairs.org/doi/10.1377/hblog20170321.059289/full/>
8. Foote MB, DeFilippis EM, **Rome BN**, Divakaran S, Yialamas MA. Use of "Doctor" Badges for Physician Role Identification During Clinical Training. *JAMA Intern Med*. 2019 Nov 1; 179(11):1582-84. Doi:10.1001/jamainternmed.2019.2416.
9. Eberly LA, Richterman A...**Rome BN** (164th of 227 authors)...Lewis EF. Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center. *Circ Heart Fail*.2019; 12(11):e006214. Doi: 10.1161/CIRCHEARTFAILURE.119.006214.
10. **Rome BN**, Tessema FA, Kesselheim AS. US Spending Associated with Transition From Daily to 3-Times-Weekly Glatiramer Acetate. *JAMA Intern Med*. 2020 Sep 1;180(9):1165-72. Doi:10.1001/jamainternmed.2020.2771.
 - Claytor JD, Redberg RF. Product Hopping—An Expensive and Wasteful Practice. [Editorial] *JAMA Intern Med*. 2020; 180(9): 1154-55. Doi:10.1001/jamainternmed.2020.2736.
11. **Rome BN**, Kesselheim AS. Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis. *Clin Infect Dis*. 2020 Oct; 71(7):1671-75. Doi:10.1093/cid/ciz1039.
 - Boucher HW, File TM, Fowler VG, Jezek A, Rex JH, Outterson K. Antibiotic Development Incentives That Reflect Societal Value of Antibiotics. [Letter to the Editor] *Clin Infect Dis*. 2021 May; 72(9):e420-21. Doi:10.1093/cid/ciaa092.
 - **Rome BN**, Kesselheim AS. Reply to Boucher, et al. [Author reply] *Clin Infect Dis*. 201 May; 72(9):e422-23. Doi:10.1093/cid/ciaa095.
12. **Rome BN**, Schnipper JL, Maviglia SM, Mueller SK. Effect of Shared Electronic Health Records on Duplicate Imaging after Hospital Transfer. *J Gen Intern Med*. 2020; 35(5):1617-19. Doi:10.1007/s11606-019-05355-2.
13. Feldman WB, **Rome BN**, Lehman LS, Kesselheim AS. Estimation of Medicare Part D Spending on Insulin for Patients with Diabetes Using Negotiated Prices and a Defined Formulary. *JAMA Intern Med*. 2020; 180(44):597-601. Doi:10.1001/jamainternmed.2019.7018.
 - Steinbrook R. Decreasing Medicare Spending on Prescription Drugs. [Editorial] *JAMA Intern Med*. 2020; 180(4): 601. Doi:10.1001/jamainternmed.2019.7064.
14. **Rome BN**, Kesselheim AS. Federal Spending on Off-Patent Drugs That Lack Generic Competition. *J Gen Intern Med*. 2021 Mar; 36(3):821-23. Doi:10.1007/s11606-020-05752-y.
15. **Rome BN**, Lee CC, Kesselheim AS. Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018. *Clin Pharmacol Ther*. 2021 Feb; 109(2):367-71. Doi:10.1002/cpt.1983.

16. **Rome BN**, Gagne JJ, Avorn J, Kesselheim AS. Non-Warfarin Oral Anticoagulant Copayments and Adherence in Atrial Fibrillation: A Population-Based Cohort Study. *Am Heart J*. 2021 Mar; 233:109-121. Doi:10.1016/j.ahj.2020.12.010.
17. Raimond VC, Feldman WB, **Rome BN**, Kesselheim AS. Why France Spends Less than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation. *Milbank Q*. 2021 Mar; 99(1):240-272. Doi: 10.1111/1468-0009.12507.
18. Walsh BS, Sarpatwari A, **Rome BN**, Kesselheim AS. Frequency of First Generic Drug Approvals with “Skinny Labels” in the United States. *JAMA Intern Med*. 2021 Jul 1; 181(7):995-7. Doi: 10.1001/jamainternmed.2021.0484.
19. Patel AN, Kesselheim AS, **Rome BN**. Frequency of Generic Drug Price Spikes and Impact on Medicaid Spending. *Health Aff*. 2021 May; 40(5):779-85. Doi: 10.1377/hlthaff.2020.02020.
20. **Rome BN**, Feldman WB, Desai RJ, Kesselheim AS. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs. *JAMA Netw Open*. 2021 May 3; 4(5):e218816. Doi: 10.1001/jamanetworkopen.2021.8816.
21. Feldman WB, **Rome BN**, Raimond VC, Gagne JJ, Kesselheim AS. Estimating Rebates and Other Discounts Received by Medicare Part D. *JAMA Health Forum*. 2021;2(6):e210626. Doi: 10.1001/jamahealthforum.2021.0626.
22. Gunter SJ**, Kesselheim AS, **Rome BN**. Market Exclusivity and Changes in Competition and Prices Associated with the US Food and Drug Administration Unapproved Drug Initiative. *JAMA Intern Med*. 2021 Aug 1; 181(8):1124-26. Doi: 10.1001/jamainternmed.2021.1989.
23. **Rome BN**, Lee CC, Gagne JJ, Kesselheim AS. Factors Associated with Generic Drug Uptake in the United States, 2012 to 2017. *Value Health*. 2021 Jun; 24(6):804-11. Doi: 10.1016/j.jval.2020.12.020.
24. **Rome BN**, Gagne JJ, Kesselheim AS. Association of California’s Prescription Drug Coupon Ban with Generic Drug Use. *JAMA*. 2021 Jun 15; 325(23):2399-2402. Doi: 10.1001/jama.2021.6568.
25. Gyawali B, **Rome BN**, Kesselheim AS. Regulatory and Clinical Consequences of Negative Confirmatory Trials of Accelerated Approval Cancer Drugs: Retrospective Observational Study. *BMJ*. 2021 Sep 8;374:n1959. Doi: 10.1136/bmj.n1959.
26. Bendicksen L, **Rome BN**, Avorn J, Kesselheim AS. Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards. *Milbank Q*. 2021 Dec;99(4):1162-97. Doi: 10.1111/1468-0009.12533.
27. **Rome BN**, Avorn J, Kesselheim AS. Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic. *J Gen Intern Med*. 2021 Dec; 36(12):3918-21. Doi: 10.1007/s11606-021-07144-2.
28. **Rome BN**, Feldman WB, Fischer MA, Desai RJ, Avorn J. Influenza Vaccine Uptake in the Year After Concurrent vs Separate Influenza and Zoster Immunization. *JAMA Netw Open*. 2021;4(11):e2135362. Doi: 10.1001/jamanetworkopen.2021.35362.
29. **Rome BN**, Feldman WB, Kesselheim AS. Medicare Spending on Drugs with Accelerated Approval, 2015-2019. *JAMA Health Forum*. 2021;2(12):e213937; Doi: 10.1001/jamahealthforum.2021.3937.
30. **Rome BN**, Kesselheim AS. Raising Medicaid Rebates For Drugs With Accelerated Approval. *Health Aff*. 2021; 40(12):1935-42. Doi: 10.1377/hlthaff.2021.00762.
31. Feldman WB, **Rome BN**, Brown BL, Kesselheim AS. Payer-Specific Negotiated Prices for Prescription Drugs at Top-Performing US Hospitals. *JAMA Intern Med*. 2022 Jan 1; 182(1):83-86. Doi: 10.1001/jamainternmed.2021.6445.
32. Walsh BS**, Kesselheim AS, Sarpatwari A, **Rome BN**. Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling. *J Clin Oncol*. 2022 Apr 1; 40(10):1102-10. Doi: 10.1200/JCO.21.02139.
33. Gunter SJ**, Kesselheim AS, **Rome BN**. Medicaid Spending on Drugs Marketed without US Food and Drug Administration Approval in 2020. *JAMA Intern Med*. 2022 Mar 1; 182(3):342-345. Doi: 10.1001/jamainternmed.2021.7614.

34. **Rome BN**, Sarpatwari A, Kesselheim AS. State Laws and Generic Substitution in the Year after New Generic Competition. *Value Health*. 2022 Oct; 25(10):1736-42. Doi: 10.1016/j.jval.2022.03.012.
35. **Rome BN**, Egilman AC, Kesselheim AS. Trends in Prescription Drug Launch Prices, 2008-2021. *JAMA*. 2022 Jun; 327(21):2145-47. Doi: 10.1001/jama.2022.5542.
 - Ybarra M, Weissman R. Recent Trends in Prescription Drug Launch Prices. [Letter to the Editor. *JAMA*. 2022 Oct 4; 328(13):1352. Doi: 10.1001/jama.2022.13826.
 - **Rome BN**, Egilman AC, Kesselheim AS. Recent Trends in Prescription Drug Launch Prices – Reply. *JAMA*. 2022 Oct 4; 328(13):1352-53. Doi: 10.1001/jama.2022.13828
36. Lalani HS**, Kesselheim AS. **Rome BN**. Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company. *Ann Intern Med*. 2022 Jul; 175(7):1053-55. Doi: 10.7326/M22-0756. Erratum in *Ann Intern Med*. 2022; 175(9):1342.
 - Selected as American College of Physicians Best of Annals 2022.
37. Foote MB, Jain N, **Rome BN**, DeFilippis EM, Powe CE, Yialamas MA. Association of Perceived Role Misidentification with Use of Role Identity Badges Among Resident Physicians. *JAMA Netw Open*. 2022 Jul; 5(7):e2224236. Doi: 10.1001/jamanetworkopen.2022.24236.
38. Jain N, **Rome BN**, Foote MB, DeFilippis EM, Powe CE, Yialamas MA. Sex-Based Role Misidentification and Burnout of Resident Physicians: An Observational Study. *Ann Surg*. 2022 Aug 1;276(2):404-408. Doi: 10.1097/SLA.0000000000004599.
39. Feng K**, Kesselheim AS, Russo M, **Rome BN**. Patient Out-of-Pocket Costs Following the Availability of Biosimilar Versions of Infliximab. *Clin Pharmacol Ther*. 2023 Jan; 113(1):90-97. Doi: 10.1002/cpt.2763
40. Egilman AC, Van de Wiele VL, **Rome BN**, Darrow JJ, Tu SS, Kesselheim AS, Sarpatwari A. Frequency of Approval and Marketing of Biosimilars with a Skinny Label and Associated Medicare Savings. *JAMA Intern Med*. 2023 Jan 1; 183(1):82-84. Doi: 10.1001/jamainternmed.2022.5419.
41. Egilman AC, Kesselheim AS, **Rome BN**. Estimated Medicare Part B Savings From Inflationary Rebates. *JAMA*. 2023 Jan 3; 329(1):89-92. Doi: 10.1001/jama.2022.20189.
42. **Rome BN**, Nagar S, Egilman AC, Wang J, Feldman WB, Kesselheim AS. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022. *JAMA Health Forum*. 2023; 4(1):e225218. Doi: 10.1001/jamahealthforum.2022.5218.
43. Wang J, Lee CC, Kesselheim AS, **Rome BN**. Estimated Medicaid Spending on Original and Citrate-Free Adalimumab from 2014 through 2021. *JAMA Intern Med*. 2023 Mar 1;183(3):275-276. Doi: 10.1001/jamainternmed.2022.6299.
44. **Rome BN**, Gunter SJ**, Kesselheim AS. Market Dynamics of Authorized Generics in Medicaid from 2014 to 2020. *Health Serv Res*. 2023 Feb 23. Online ahead of print. Doi: 10.1111/1475-6773.14145.
45. Lalani HS**, Nagar S, Sarpatwari A, Barenie RE, Avorn J, **Rome BN**, Kesselheim AS. US public investment in development of mRNA covid-19 vaccines: retrospective cohort study. *BMJ*. 2023 Mar 1; 380:e073747. Doi: 10.1136/bmj-2022-073747.
46. **Rome BN**, Egilman AC, Patel NG, Kesselheim AS. Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone. *Value Health*. 2023 Mar;26(3):370-377. Doi: 10.1016/j.jval.2022.08.013.
47. Walsh BS**, Kesselheim AS, **Rome BN**. Medicaid Spending on Antiretrovirals from 2007 Through 2019. *Clin Infect Dis*. 2023 Mar 4;76(5):833-841. Doi: 10.1093/cid/ciac833.
48. Deshmukh AD**, Kesselheim AS, **Rome BN**. Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021. *JAMA Health Forum*. 2023 Mar 3;4(3):e230217. Doi: 10.1001/jamahealthforum.2023.0217.

49. Cliff ERS, Kesselheim AS, **Rome BN**, Feldman WB. Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020. *JAMA Netw Open*. 2023 Apr 3;6(4):e237467. Doi: 10.1001/jamanetworkopen.2023.7467.
50. Egilman AC, Rome BN, Kesselheim AS. Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare. *JAMA*. 2023 Apr 18;329(15):1283-1289. Doi: 10.1001/jama.2023.4034.

Other peer-reviewed publications

1. Suter LG, Paltiel AD, **Rome BN**, Solomon DH, Golovaty I, Gerlovin H, Katz JN, Losina E. Medical Device Innovation – Is “Better” Good Enough? *N Eng J Med*. 2011; 365(16):1464-66. Doi:10.1371/journal.pone.0062709.
2. Losina E, Collins JE, Daigle ME, Donnell-Fink LA, Prokopetz JJ, Strnad D, Lerner V, **Rome BN**, Ghazinouri R, Skoniecki DJ, Katz JN, Wright J. The AViKA (Adding Value in Knee Arthroplasty) postoperative care navigation trial: rationale and design features. *BMC Musculoskelet Disord* 2013; 14(290). PubMed PMID 24119081
3. **Rome BN**, Kramer DB, Kesselheim AS. Approval of high-risk medical devices in the US: implications for clinical cardiology. *Curr Cardiol Rep*. 2014; 16(6):489. Doi:10.1007/s11886-014-0489-0.
4. **Rome BN**, Avorn J. Drug Evaluation during the Covid-19 Pandemic. *New Engl J Med*. 2020; 382(24): 2282-84. Doi:10.1056/NEJMp2009457.
5. Feldman WB, **Rome BN**, Avorn J, Kesselheim AS. The Future of Drug-Pricing Transparency. *New Eng J Med*. 2021 Feb 11; 384(6):489-91. Doi:10.1056/NEJMp2033734.
6. **Rome BN**, Kesselheim AS. Will Ending the Medicaid Drug Rebate Cap Lower Drug Prices? *JAMA Intern Med*. 2021 Aug 1; 181(8):1034-35. Doi: 10.1001/jamainternmed.2021.2696.
7. **Rome BN**, Sarpatwari A. Promoting Biosimilar Competition by Revising Medicare Reimbursement Rules (Invited Commentary). *JAMA Netw Open*. 2021;4(11):e2134463. Doi: 10.1001/jamanetworkopen.2021.34463.
8. Lalani HS**, Kesselheim AS, **Rome BN**. Direct-to-Consumer Generic Drugs: A Maverick Approach or Another Exposure of Market Failures? *Ann Intern Med*. 2022 Jun; 175(6):890-91. Doi: 10.7326/M22-0740.
9. Bendicksen L, Kesselheim AS, **Rome BN**. The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs Chest. 2022 Aug; 162(2):433-35. Doi: 10.1016/j.chest.2022.02.048.
10. Hwang TJ, Kesselheim AS, **Rome BN**. New Reforms to Prescription Drug Prices in the US: Opportunities and Challenges. *JAMA*. 2022 Sep 20; 328(11):1041-42. Doi: 10.1001/jama.2022.15268.
11. **Rome BN**, Kesselheim AS. Biosimilar Competition for Humira is Here: Signs of Hope Despite Early Hiccups. *Arthritis Rheumatol*. 2023 Apr 7. Epub ahead of print. Doi: 10.1002/art.42520.

Non-peer reviewed scientific or medical publications/materials in print or other media

Proceedings of meetings or other non-peer reviewed scholarship

1. **Rome BN**. Drug Approval During the Covid-19 Pandemic: Following the Evidence. Hearing before the US House of Representatives Committee on Science, Space, and Technology, Subcommittee on Investigations and Oversight (Rep Foster, Chairman). Repurposing Therapeutic Drugs for Covid-19: Research Challenges and Opportunities. July 19, 2020. Online via Videoconferencing. Available at: <https://science.house.gov/hearings/repurposing-therapeutic-drugs-for-covid-19-research-challenges-and-opportunities>.

Reviews, chapters, monographs and editorials

1. **Rome BN**, Losina E. Epidemiology of Ageing (Socioeconomic Impact). In: Guglielmi G, Peh WCG, Guermazi A, editors. Geriatric Imaging. . Heidelberg, Germany: Springer, 2013. pp. 1-18.

Letters to the Editor

1. **Rome BN**, Feldman WB, Kesselheim AS. Drug Prices, Rebates, and Discounts. JAMA. 2020; 324(4):399. Doi: 10.1001/jama.2020.7983.

Professional educational materials or reports, in print or other media

1. Feldman WB, **Rome BN**. Ed. Avorn J, Fischer MA, Kim D, Dancel E. "Immunizing older adults: The latest recommendations on flu, pneumococcal pneumonia, shingles, and other preventable conditions," Module for academic detailers, Alosa Health, Boston, MA; 2020. Available <https://alosahealth.org/clinical-modules/immunizations/>.
2. Jering K, Cunningham JW. Ed. Fischer MA, Avorn J, Kim D, **Rome BN**, Whitney D, Dancel E. Heart Failure: Improving Outcomes in Primary Care. Module for academic detailers, Alosa Health, Boston, MA; 2021. Available <https://alosahealth.org/clinical-modules/heartfailure/>
3. Chaitoff A, Mirsky J, Narasimmaraj P, Pollack R. Ed. **Rome BN**, Kim D, Avorn J, Dancel E. Preventing cardiovascular disease: Evidence-based recommendations on risk, lipid-lowering drugs, aspirin, and lifestyle." Module for academic detailers, Alosa Health, Boston, MA; 2021. Available <https://alosahealth.org/clinical-modules/cvdprevention/>
4. Kung S, Landfeld C. Ed. **Rome BN**, Avorn J, Whitney D, Dancel E. Management of opioid use disorder in primary care. Module for academic detailers, Alosa Health, Boston, MA; 2022. Available <https://alosahealth.org/clinical-modules/oud/>
5. Chaitoff A. Ed. Avorn J, **Rome BN**, Whitney D, Dancel E. Managing type 2 diabetes: New guidelines are transforming medication use. Module for academic detailers, Alosa Health, Boston, MA; 2022. Available <https://alosahealth.org/clinical-modules/diabetes/>.

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

2. Lalani HS**, Kesselheim AS, Desai RJ, **Rome BN**. Patient Out-of-Pocket Costs for Brand-Name Clinician-Administered Drugs Doubled from 2009-2018 [Poster]. Society of General Internal Medicine Annual Meeting. April 6-9, 2022. Orlando, FL.

Narrative Report

I am an Instructor in Medicine at HMS and an Associate Physician in Pharmacoepidemiology and Pharmacoeconomics at BWH. My area of excellence is Investigation and my significant supporting activities are Administration and Institutional Service and Special Merit in Education. My research bridges pharmacoepidemiology and health policy, providing empiric evidence to evaluate how federal and state policies influence the regulation, use, and cost of prescription drugs and the resulting effects on patient access, affordability, and clinical outcomes.

My research within the Program On Regulation, Therapeutics, And Law (PORTAL) has focused on several areas. I have examined the US Food and Drug Administration process for approving new drugs, including the accelerated approval pathway and proposed policies to incentivize development of new antibiotics and treatments for rare diseases. I have studied the impact of generic and biosimilar competition on drug prices and patient affordability for essential medications, identifying strategies that

are sometimes used to delay or limit such competition. Finally, I have studied the relationship between drug prices, high out-of-pocket costs for patients, and patient adherence.

My work has been published in leading general medicine and health policy journals including *The New England Journal of Medicine*, *JAMA*, *BMJ*, and *Health Affairs*. I have also been invited to discuss my research with academics, patient advocacy groups, and state and federal policy makers. In 2020, I was invited to testify in before Congress on the FDA regulation of drugs during the Covid-19 pandemic. I was selected by the National Academy of Medicine as an Emerging Leader in Health and Medicine Scholar from 2022-2025.

I have served as the principal or co-principal investigator for multiple foundation grants, and I led our team in successful competitive bids to serve as strategic consultants for 6 states implementing prescription drug affordability boards, work that is funded by the National Academy for State Health Policy. My work informed landmark drug pricing reforms passed by Congress in the Inflation Reduction Act of 2022. I continue to advise the Centers for Medicare and Medicaid Services on implementation of these reforms and consult with federal and state policy makers about additional policies to improve the affordability of prescription drugs.

Clinically, I practice primary care at the Phyllis Jen Center for Primary Care, where I manage a panel of primary care patients, with a focus on adults with complex chronic conditions. I also precept residents, serving as the primary outpatient clinical mentor for 2-3 internal medicine residents each year. My experience caring for patients directly informs my research interests in ensuring safe and effective medications are affordable and accessible, particularly for the most vulnerable patient populations.

My leadership roles include serving as the Assistant Director for Health Services Research, overseeing and assisting with research by faculty and trainees within PORTAL. I am a Site Co-Director for the T32-funded HMS Fellowship in General Medicine and Primary Care, recruiting and providing research mentoring to trainees in pharmacoepidemiology and health policy. I am also the Assistant Director of the Management and Leadership Pathway for the BWH Internal Medicine Residency, organizing a 12-week curriculum and providing career mentoring to participating residents. I also serve as a member of the HMS admissions committee.

I am dedicated to teaching and mentoring students, residents, and post-doctoral trainees. My teaching activities include primary care precepting for residents; direct research mentoring for many trainees within PORTAL; and teaching epidemiology and health policy in several HMS courses. I am also the Assistant Director and teach in a course at the Harvard T.H. Chan School of Public Health on research using longitudinal healthcare databases.